Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Better Living for People With Alzheimer's: One of a Kind Device and Opportunity to Make a Difference

CHESHIRE, Conn. - July 22, 2021 - (Newswire.com)

Recombinant Technologies, an innovative, preclinical stage biotechnology company (www.recombtech.com) from Cheshire, CT, has kickstarted a crowdfunding effort through the crowdfunding enabler Start Engine (https://www.startengine.com/recombinant-technologies). There are an estimated 5,500,000 people in the U.S. who have Alzheimer's disease. In order to help these individuals with Alzheimer's, Recombinant Technologies (RT) has been exploring novel avenues for effectively and safely treating Alzheimer's and other beta-amyloidopathy diseases. RT has developed an innovative treatment, known as the AmyTrap, that addresses the cause of the disease rather than the symptoms. Current Alzheimer's therapeutics target the symptoms rather than the cause of the disease, so RT believes its flagship therapeutic, AmyTrap, will address this unmet medical need. This announcement follows successful proof-of-concept studies for Recombinant Technologies' innovative AmyTrap drug candidates. These candidates have been shown in preclinical experiments to trap and clear Alzheimer's disease-causing Aβ-amyloid plaques, thereby restoring memory by returning the natural balance of beta-amyloid in the body.

In addition, RT has designed and developed two types of devices coated with the patent-protected Amytrap (the devices appropriately named 'AmyTrappers'), which traps amyloid from circulation. Proof of concept for this device has already been demonstrated subject to completion of animal testing. The following video best illustrates the Amytrapper device https://www.recombtech.com/#. These proposed innovative devices trap amyloid from circulation (just like dialysis to remove urea in patients with kidney failure), which may lead to a novel treatment strategy that improves the lives of patients with AD. As part of the fund-raising, RT has recruited SA Capital Partners LLC, New York and Chicago to expedite the efforts. SA Capital Partners is an innovative financial services firm that specializes in mergers & acquisitions advisory and capital raising for lower middle market businesses https://www.sacapitalpartnersllc.com. By working with SA Partners to attract investors to fund additional development studies, this one-of-a-kind, promising and proprietary AmyTrap breakthrough technology can be fast-tracked through the development pipeline, says Inventor, Founder and CEO of Recombinant Technologies, Dr. Pazhani Sundaram. Dr. Sundaram's prior research efforts have produced marketable health products. This innovative Bio-Technology company will change the entire landscape for the treatment of Alzheimer's, said CEO of SA Capital Partners, LLC, Maz Pawar.

"Through a rigorous, peer-reviewed evaluation process by the National Institute on Aging, National Institutes of Health, Recombinant Technologies was previously granted funding to demonstrate the efficacy of its AmyTrap drug candidates and devices in proof-of-concept model experiments,'' Dr. Sundaram stated. "I am excited that we are on target to accomplish a major goal in finding a therapeutic strategy. With the acceptance of amyloid beta clearance as a treatment strategy for Alzheimer's Disease in the form of recent FDA approval for Biogen's Aduhelm (Adecanumab), Amytrap and Amytrappers should receive increased traction from the scientific and investment community," he added.  Recombinant Technologies Inc has been granted a patent from USPTO and owns the intellectual property on these molecules and devices. 




Press Release Service by Newswire.com

Original Source: Better Living for People With Alzheimer's: One of a Kind Device and Opportunity to Make a Difference
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.